Skip to content
drillr.ai
Sign up

NTHI

NEONC TECHNOLOGIES HOLDINGS, INC.

NASDAQ · Healthcare · Biotechnology · US

$3.26
−4.40%
Ask drillr

  • Sep 17, 2026, 12:00 UTC

    NeOnc Technologies Holdings redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for cash at an aggregate stated value of $6.0 million.

    Source:

  • Sep 16, 2026, 01:49 UTC

    Thomas C. Chen, CEO, Director, and 10% owner of Neonc Technologies Holdings, acquired $39,999 of the company's common stock in two transactions on September 11 and September 14, 2026, through an IRA.

    Source:

  • Sep 15, 2026, 13:53 UTC

    NeOnc Technologies CEO purchased an additional 37,000 shares of the company's common stock.

    Source:

  • Sep 10, 2026, 14:31 UTC

    NEONC Technologies Holdings, Inc. entered into securities purchase agreements with certain institutional investors to sell 2,610,715 shares of common stock, pre-funded warrants for up to 960,715 shares, and accompanying warrants for up to 3,571,430 shares at a combined price of $4.20 per share and accompanying warrant, for gross proceeds of approximately $15 million.

  • Aug 21, 2026, 00:00 UTC

    NeonC Technologies Holdings, Inc. appointed Nasim Shomali as a member of its Board of Directors, effective July 1, 2026, and as a member of the Audit Committee, effective August 18, 2026.

  • Aug 18, 2026, 14:18 UTC

    NeOnc Technologies Holdings CEO Amir Heshmatpour purchased 12,000 shares on August 14 and 3,000 shares on August 17, 2026, on the open market.

    Source:

  • Aug 12, 2026, 12:00 UTC

    NeOnc Technologies reported positive topline Phase 2a results for its intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, meeting the primary endpoint of six-month progression-free survival.

    Source:

  • Jun 23, 2026, 13:00 UTC

    NeOnc Technologies received Investigational New Drug (IND) approval from the Department of Health – Abu Dhabi for its lead candidate NEO100, covering multiple clinical trial protocols.

    Source:

  • Jun 16, 2026, 17:49 UTC

    The Department of Health - Abu Dhabi granted Investigational New Drug (IND) authorization for NeOnc Technologies Holdings' NEO212, an oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors.

    Source:

  • Jun 12, 2026, 00:00 UTC

    NeonC Technologies Holdings, Inc. signed a private placement agreement to sell up to 6,000 shares of Series A Convertible Preferred Stock for up to $5,000,000.